TY  - JOUR 
AU  - Fernandez-Perez, M.P.
AU  - Perez-Navarro, E.
AU  - Alonso-Gordoa, T.
AU  - Conteduca, V.
AU  - Font, A.
AU  - Vázquez Estévez, Sergio
AU  - González-del-Alba, A.
AU  - Wetterskog, D.
AU  - Antonarakis, E.S.
AU  - Mellado, B.
AU  - Fernández Calvo, Ovidio
AU  - Méndez-Vidal, M.J.
AU  - Climent, M.A.
AU  - Duran, I.
AU  - Gallardo, E.
AU  - Rodriguez Sanchez, A.
AU  - Santander, C.
AU  - Sáez, M.I.
AU  - Puente, J.
AU  - Tudela, J.
AU  - Martínez, A.
AU  - López-Andreo, M.J.
AU  - Padilla, J.
AU  - Lozano, R.
AU  - Hervas, D.
AU  - Luo, J.
AU  - de Giorgi, U.
AU  - Castellano, D.
AU  - Attard, G.
AU  - Grande, E.
AU  - Gonzalez-Billalabeitia, E.
PY  - 2023
SN  - 1097-0045
UR  - http://hdl.handle.net/20.500.11940/20971
AB  - Background: There is a considerable need to incorporate biomarkers of resistance to new antiandrogen agents in the management of castration-resistant prostate cancer (CRPC). Methods: We conducted a phase II trial of enzalutamide in first-line...
LA  - eng
KW  - Humans
KW  - Male
KW  - Biomarkers, Tumor
KW  - Neoplastic Cells, Circulating
KW  - Nitriles
KW  - Prognosis
KW  - Prostate-Specific Antigen
KW  - Prostatic Neoplasms, Castration-Resistant
KW  - Receptors, Androgen
TI  - A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
DO  - 10.1002/pros.24469
T2  - Prostate
M2  - 376
KW  - AS Lugo
KW  - CHULA
KW  - AS Ourense
KW  - CHUO
VL  - 83
ER  -